NasdaqGM:TVTXBiotechs
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results
Travere Therapeutics (TVTX) has witnessed significant developments, including the FDA's decision not to call an advisory committee meeting for the sNDA of FILSPARI®, while the drug is still under review with a crucial action date in 2026. These positive regulatory signals, coupled with promising DUPLEX Study results indicating reduced kidney failure risks, likely reinforced investor optimism, contributing to its 49% share price increase last quarter. The company's financial performance,...